(Z)-4EGI-1 is an inhibitor of eIF4E/eIF4G interaction and translation initiation; it exhibits anticancer activity by inhibiting cancer cell proliferation (IC50 = 15.3 μM in CRL-2351 breast cancer cells; IC50 = 11.6 μM in CRL-2813 melanoma cells) and downregulating the expression of regulatory proteins such as cyclin D1, cyclin E, and Survivin.